The prevention against chronic antibody mediated rejection on graft endothelial
Project/Area Number |
26462458
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Aichi Medical University (2015-2016) Nagoya University (2014) |
Principal Investigator |
Iwasaki Kenta 愛知医科大学, 医学部, 准教授 (10508881)
|
Co-Investigator(Kenkyū-buntansha) |
小林 孝彰 愛知医科大学, 医学部, 教授 (70314010)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 移植免疫 / 免疫順応 / 腎移植 / シグナル伝達 / 細胞保護 / HLA-class II / HLA / Accommodation / Signal tranduction |
Outline of Final Research Achievements |
Donor-specific antibody (DSA), particularly against HLA class II, is a major cause of chronic antibody-mediated rejection (CAMR) after transplantation, although ABO-incompatible kidney transplantation has recently demonstrated favorable graft outcomes. The condition of no injury even in the presence of anti-donor antibody has been referred to as “accommodation”, which would be one of the key factors for successful long-term graft survival. The purpose of this study was to analyze the beneficial effect of anti-blood group A/B antibody ligation on endothelial cells against HLA-DR antibody-mediated, complement-dependent cytotoxicity (CDC). Pre-incubation with anti-blood group A/B antibody had resistance to HLA-DR antibody-mediated CDC. This finding was ascribed to decreased expression of HLA-DR by post-translational regulation and increased expression of CD55/59, which was related to ERK and mTOR pathway inhibition.
|
Report
(4 results)
Research Products
(7 results)